AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-FreeSurvival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial (pdf 66KB)

January 4, 2012

Printer-friendly version

1. AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-FreeSurvival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial (pdf 66KB)

---

• Message
• Business Philosophy
• VISION 2015
• CSR-Based Management
• Governance & Internal Control
• Business Activities
• Corporate Profile
• Disclosure Policy
• News Releases
  • 2013
  • 2012
  • 2011
  • Past news
  • Yamanouchi
  • Fujisawa
• Information Service
• Corporate Advertising